Hepatocellular Carcinoma

Gastrointestinal Cancer
Hepatocellular Carcinoma
- Resectable
- Locoregional Tx Appropriate
- Systemic Tx Appropriate
  - Immunotherapy Eligible
    - First Line
      - VICCGI25054
        Phase 2a Study of RBS2418 with Tremelimumab + Durvalumab in Advanced Unresectable HCC
        
        *• Child Pugh A [very limited slots for B7], Plts 75K+, CrCl 60+, no main portal vein involvement, *no active HEP C (need to have SVR), controlled hep B
        • While not tissue biomarker selective, it is tissue biomarker stratified, so pre-enrollment BIOPSY for participation, so, referring providers, [hepatology/HBS/IR,] please keep this in mind when weighing whether to biopsy (if they have archival tissue from an outside biopsy or previous surgery, then that will sometimes suffice depending how much is there)
      - VICC-ITGIT23272
        STRIDE in CP-B: Ph II Study of Tremelimumab & Durvalumab in aHCC w/ Child-Pugh-B Cirrhosis
        
        Key eligibility
        
        • Child Pugh B7 or B8, Plts 60K+, no restrictions on vascular invasion, CrCl >40
      - VICCGIP25073
        Phase 1/2 Study of Pumitamig +/- Ipi in Pts w/1L Advanced or Unresectable HCC
        
        • Child Pugh A, Plts 60K+, CrCl 40+, no active HEP C (need to have SVR), controlled hep B, no therapeutic AC or Anti-Platelet (outside of baby aspirin)
        • *Biopsy proven HCC required for participation, so, referring providers, [hepatology/HBS/IR,] please keep this in mind when weighing whether to biopsy
        • *EGD within 6 months and varices, if present, s/p definitive treatment (per institutional standards). So even if already on beta-blocker, still need an updated EGD assessment within 6 months of enrollment.
    - Second Line
    - Third Line
  - Immunotherapy Ineligible
    - First Line